Comparative Effectiveness of Ustekinumab Versus Vedolizumab in Treating Crohn's Disease After Failure of Anti-TNF Agents: Real-World Evidence

被引：0
|
作者：
Alamer, A. [1 ]
Al Lehaibi, L. [2 ]
Alomar, M. [2 ]
Aldhuwayan, F. [2 ]
Alshouish, S. [2 ]
Al-Ali, A. [3 ]
Almudhry, Z. [4 ]
Almulhim, A. [5 ]
Althagafi, A. [6 ]
Aldosari, S. [7 ]
Alameel, T. [8 ]
机构：
[1] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Alkharj, Saudi Arabia
[2] Eastern Hlth Cluster Dammam Med Complex, Dept Clin Pharm, Dammam, Saudi Arabia
[3] Eastern Hlth Cluster Dhahran Eye Specialist Hosp, Dept Clin Pharm, Dhahran, Saudi Arabia
[4] Eastern Hlth Cluster Dammam Med Complex, Dept Med, Dammam, Saudi Arabia
[5] King Faisal Univ, Dept Pharm Practice, Coll Clin Pharm, Alhofuf, Saudi Arabia
[6] King Abdulaziz Univ, Dept Pharm Practice, Fac Pharm, Jeddah, Saudi Arabia
[7] Prince Sattam Bin Abdulaziz Univ, Dept Clin Pharm, Coll Pharm, Alkharj, Saudi Arabia
[8] King Fahad Specialist Hosp Dammam, Dept Med, Dammam, Saudi Arabia
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P688
引用
收藏
页码：I1297 / I1297
页数：1
相关论文
共 50 条
  • [41] Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn's disease patients failure to TNF inhibitors
    Onali, S.
    Pugliese, D.
    Caprioli, F. A.
    Orlando, A.
    Biancone, L.
    Nardone, O. M.
    Imperatore, N.
    Fiorino, G.
    Cappello, M.
    Viola, A.
    Principi, M. B.
    Bezzio, C.
    Aratari, A.
    Carparelli, S.
    Mazzuoli, S.
    Manguso, F.
    Grossi, L.
    Bodini, G.
    Ribaldone, D.
    Mocci, G.
    Minerba, L.
    Favale, A.
    Grova, M.
    Scucchi, L.
    Segato, S.
    Fries, W.
    Castiglione, F.
    Armuzzi, A.
    Fantini, M. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I542 - I543
  • [42] Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn's disease patients failure to TNF inhibitors
    Onali, S.
    Pugliese, D.
    Caprioli, F. A.
    Orlando, A.
    Biancone, L.
    Nardone, O. M.
    Imperatore, N.
    Fiorino, G.
    Cappello, M.
    Viola, A.
    Principi, M. B.
    Bezzio, C.
    Aratari, A.
    Carparelli, S.
    Mazzuoli, S.
    Manguso, F.
    Grossi, L.
    Bodini, G.
    Ribaldone, D.
    Mocci, G.
    Minerba, L.
    Favale, A.
    Grova, M.
    Scucchi, L.
    Segato, S.
    Fries, W.
    Castiglione, F.
    Armuzzi, A.
    Fantini, M. C.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I542 - I543
  • [43] Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn's disease: a multi-centre retrospective cohort study
    Townsend, T.
    Razanskaite, V.
    Michail, S.
    Morgan, J.
    Davies, M.
    Storey, D.
    Watters, C.
    Penman, D.
    Swaminathan, M.
    Sabine, J.
    Chapman, A.
    Vyas, A.
    Reilly, I.
    Flanagan, P.
    Bodger, K.
    Subramanian, S.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S407 - S408
  • [44] Letter: effectiveness of ustekinumab or vedolizumab in Crohn's disease following anti-TNF failure-getting closer to the truth. Authors' reply
    Biemans, Vince B. C.
    Hoentjen, Frank
    Pierik, Marieke J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 52 (07) : 1255 - 1256
  • [45] Real-World Comparison of the Effectiveness between Ustekinumab and Vedolizumab in Patients with Ulcerative Colitis Exposed to at least One Anti-TNF Agent
    Fumery, Mathurin
    Serrero, Melanie
    Bouguen, Guillaume
    Amiot, Aurelien
    Altwegg, Romain
    Nachury, Maria
    Vuitton, Lucine
    Treton, Xavier
    Caillo, Ludovic
    Pereira, Bruno
    Buisson, Antony
    JOURNAL OF CROHNS & COLITIS, 2024, 18 (10): : 1615 - 1621
  • [46] USTEKINUMAB IS ASSOCIATED WITH BETTER EFFECTIVENESS OUTCOMES WHEN COMPARED TO VEDOLIZUMAB IN CROHN'S DISEASE PATIENTS WITH PRIOR FAILURE TO ANTI-TNF: A COMPARATIVE EFFECTIVENESS STUDY FROM THE DUTCH ICC REGISTRY
    Biemans, Vince
    Van der Woude, Christien Janneke
    Dijkstra, Gerard
    Meulen-de Jong, Andrea V.
    Lowenberg, Mark
    de Boer, Nanne
    Oldenburg, Bas
    Srivastava, Nidhi
    Jansen, Jeroen M.
    Bodelier, Alexander
    West, Rachel
    de Vries, Annemarie C.
    Haans, Jeoffrey
    De Jong, Dirk J.
    Hoentjen, Frank
    Pierik, Marie
    GASTROENTEROLOGY, 2020, 158 (06) : S207 - S208
  • [47] Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease
    Srinivasan, Ashish
    van Langenberg, Daniel
    De Cruz, Peter
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : E69 - E69
  • [48] WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
    Rayer, Cassandra
    Roblin, Xavier
    Laharie, David
    Flamant, Mathurin
    Dewitte, Marie
    Fumery, Mathurin
    Caron, Benedicte
    Viennot, Stephanie
    Pariente, Benjamin
    Laurent, Siproudhis
    Peyrin-Biroulet, Laurent
    Bouguen, Guillaume
    GASTROENTEROLOGY, 2020, 158 (06) : S958 - S958
  • [49] Which second-line biologic after anti-TNF failure during Crohn's disease: Ustekinumab or vedolizumab, a multicentre retrospective study
    Rayer, C.
    Roblin, X.
    Laharie, D.
    Caron, B.
    Flamant, M.
    Dewitte, M.
    Fumery, M.
    Viennot, S.
    Bourreille, A.
    Pariente, B.
    Siproudhis, L.
    Peyrin-Biroulet, L.
    Bouguen, G.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S547 - S547
  • [50] Effectiveness of ustekinumab in fistulising perianal Crohn's disease refractory or intolerant to anti-TNF
    Carpio, D.
    Calvino-Suarez, C.
    Martinez-Cadilla, J.
    Molina, G.
    Vazquez-Rey, M. T.
    Marti, E.
    Fernandez-Salgado, E.
    Acosta, M. Barreiro-de
    Hernandez, V.
    Echarri, A.
    Diz-Lois, M. T.
    Baz, A.
    JOURNAL OF CROHNS & COLITIS, 2021, 15 : S419 - S420
12345